309 related articles for article (PubMed ID: 28760367)
1. Effects of metformin on endometrial cancer: Systematic review and meta-analysis.
Meireles CG; Pereira SA; Valadares LP; Rêgo DF; Simeoni LA; Guerra ENS; Lofrano-Porto A
Gynecol Oncol; 2017 Oct; 147(1):167-180. PubMed ID: 28760367
[TBL] [Abstract][Full Text] [Related]
2. Metformin for endometrial hyperplasia: a Cochrane protocol.
Clement NS; Oliver TR; Shiwani H; Saner JR; Mulvaney CA; Atiomo W
BMJ Open; 2016 Aug; 6(8):e013385. PubMed ID: 27531741
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
5. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
6. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative effect of metformin on the endometrium--a clinical trial.
Tabrizi AD; Melli MS; Foroughi M; Ghojazadeh M; Bidadi S
Asian Pac J Cancer Prev; 2014; 15(23):10067-70. PubMed ID: 25556427
[TBL] [Abstract][Full Text] [Related]
8. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent.
Session DR; Kalli KR; Tummon IS; Damario MA; Dumesic DA
Gynecol Endocrinol; 2003 Oct; 17(5):405-7. PubMed ID: 14710588
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
10. Metformin and progestins in women with atypical hyperplasia or endometrial cancer: systematic review and meta-analysis.
Adamyan L; Pivazyan L; Isaeva S; Shapovalenko R; Zakaryan A
Arch Gynecol Obstet; 2024 Jun; 309(6):2289-2305. PubMed ID: 38503850
[TBL] [Abstract][Full Text] [Related]
11. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.
Shen ZQ; Zhu HT; Lin JF
Obstet Gynecol; 2008 Aug; 112(2 Pt 2):465-7. PubMed ID: 18669766
[TBL] [Abstract][Full Text] [Related]
12. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
13. Metformin is associated with improved survival in endometrial cancer.
Ko EM; Walter P; Jackson A; Clark L; Franasiak J; Bolac C; Havrilesky LJ; Secord AA; Moore DT; Gehrig PA; Bae-Jump V
Gynecol Oncol; 2014 Feb; 132(2):438-42. PubMed ID: 24269517
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
15. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
Shao F; Li Y; Zhao Y
Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus.
Perez-Lopez FR; Pasupuleti V; Gianuzzi X; Palma-Ardiles G; Hernandez-Fernandez W; Hernandez AV
Maturitas; 2017 Jul; 101():6-11. PubMed ID: 28539171
[TBL] [Abstract][Full Text] [Related]
17. Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis.
Xie H; Li M; Zheng Y
Gynecol Oncol; 2024 Mar; 182():15-23. PubMed ID: 38246042
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
Mitsuhashi A; Shozu M
J Obstet Gynaecol Res; 2020 Feb; 46(2):215-222. PubMed ID: 32017321
[TBL] [Abstract][Full Text] [Related]
19. Metformin Use Is Associated with Reduced Incidence and Improved Survival of Endometrial Cancer: A Meta-Analysis.
Tang YL; Zhu LY; Li Y; Yu J; Wang J; Zeng XX; Hu KX; Liu JY; Xu JX
Biomed Res Int; 2017; 2017():5905384. PubMed ID: 28409158
[TBL] [Abstract][Full Text] [Related]
20. Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer,
Wang T; Zhang J; Hu M; Zhang Y; Cui P; Li X; Li J; Vestin E; Brännström M; Shao LR; Billig H
Int J Biol Sci; 2019; 15(3):714-725. PubMed ID: 30745857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
